APT(SH:688617) Shang Hai Zheng Quan Bao·2026-02-09 19:00Core Viewpoint - Shenzhen Huatai Medical Devices Co., Ltd. has announced a share repurchase plan aimed at enhancing investor confidence and establishing a long-term incentive mechanism for sustainable development [1][5]. Group 1: Share Repurchase Plan - The total amount for the share repurchase will not be less than RMB 150 million and not exceed RMB 200 million [6]. - The source of funds for the repurchase will be the company's own funds [7]. - The repurchased shares will be used for employee stock ownership plans or equity incentives within three years after the announcement of the repurchase results [7][26]. Group 2: Repurchase Details - The maximum repurchase price is set at RMB 315 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [8][19]. - The repurchase will be conducted through the Shanghai Stock Exchange via centralized bidding [8][14]. - The repurchase period is set for 10 months from the board's approval date [9][15]. Group 3: Voting and Approval - The board meeting held on February 9, 2026, had all 9 directors present, with a unanimous vote of 9 in favor, 0 against, and 0 abstentions [3][12]. - The repurchase plan does not require shareholder approval as per the company's articles of association [12]. Group 4: Financial Impact - As of September 30, 2025, the company's total assets were approximately RMB 3.46 billion, and the equity attributable to shareholders was about RMB 2.99 billion [22]. - The planned repurchase amount represents approximately 5.78% of total assets and 6.69% of equity [22]. Group 5: Shareholder Actions - The company’s major shareholders, including directors and senior management, have no clear plans for share reduction in the next three to six months following the board's decision [10][24].